Phibro Animal Health PAHC

Reference table

1. What it is

Phibro Animal Health (Nasdaq: PAHC) researches, makes and sells animal health and mineral nutrition products, mainly for food-producing animals — poultry, swine, beef and dairy cattle, and aquaculture. Three segments: Animal Health (antimicrobials, anticoccidials, anthelmintics, nutritional specialties, vaccines for poultry/swine), Mineral Nutrition (zinc, manganese, copper, iron trace-mineral formulations) and Performance Products (specialty ingredients for personal care, industrial chemicals, catalysts). Distribution runs through its own sales offices, direct sales to integrated protein producers, and feed producers/wholesalers/distributors. Formerly Philipp Brothers Chemicals; renamed 2003, IPO 2014-04-11; headquartered Teaneck, NJ; ~1,940 employees; profile lists Jack C. Bendheim as CEO (see §9 on the apparent transition to Daniel Bendheim). Fiscal year ends June 30 (FY26 = year ending 2026-06-30).

Revenue mix (from filings in the data file — with an honest caveat):

• By product: the file's segment data is incomplete for recent years — FY25 shows only a Vaccines line of $137.2M (up from $120.9M FY24, +13.5%). The last full split on file is FY22: Animal Health $607.1M · Mineral Nutrition $259.5M · Performance Products $75.7M — Animal Health is the profit engine, roughly two-thirds of sales then. We flag rather than fabricate the current split.
• By geography (FY25): United States $739.9M (57%) · Latin America & Canada $298.6M (23%) · EMEA $160.2M (12%) · Asia Pacific $97.4M (8%). A genuinely global footprint with a US center of gravity — livestock-cycle and FX exposure, minimal China/geopolitical concentration.

The FY25 story is the ~$287M acquisition (net cash, per the FY25 cash-flow statement) — widely known to be the medicated feed additive portfolio purchased from Zoetis (context; the deal identity is not in the data file) — funded with ~$236M of new long-term debt. It is what drove revenue from $1.02B to $1.30B and what put the balance sheet question at the center of the thesis.

2. The expert thesis (traceable)

No expert-panel coverage — this note is fundamentals-driven. A search of the Synthos knowledge base returns zero claims on PAHC from any tracked voice: no bull thesis, no short thesis, nothing to reconcile. That is the honest standard for screen-surfaced names — this company entered the pipeline via a quant screen, not via conviction from a high-skill thinker.

What that means practically:

• The bull and bear cases in §3 are our own construction from the filed numbers and consensus estimates, not a synthesis of expert views.
• kb_breadth = 0, kb_claim_count = 0, kb_net_conviction = null — nothing is aggregated because nothing exists. Fabricated conviction is structurally impossible here, and none is offered.
• Conviction rating: None. A Watch verdict with no panel behind it should be treated as lower-confidence than an identically-scored name with real expert breadth.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range; the scores summarize them.

Synthos fair value = the base case, ~$43 (+26%), full range $27–$55. The Street's $49 sits above us at ~14.7× FY27E — but that "consensus" is a single converged target (high = low = median = $49), which is coverage thinness, not agreement; we discount it accordingly and anchor our own 13× on the leverage and the growth fade. The asymmetry (+61% / −21%) is what earns Watch rather than Avoid: the setup is attractive if a trigger confirms. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). PAHC is neither — it is a leveraged consolidator in a mature industry:

• Forward growth: consensus revenue $1.50B (FY26E) → $1.55B (FY27E) → $1.60B (FY28E) → $1.65B (FY29E) → $1.70B (FY30E) — a ~3.2% CAGR. Consensus adjusted EPS $3.07 → $4.83 over the same span (~12%/yr), driven by margin and deleveraging, not top-line.
• Acceleration (the 2nd derivative) is negative: quarterly revenue growth has faded +39.7% (Q1 FY26 YoY) → +20.9% (Q2) → +10.3% (Q3), and the Q4 FY26 estimate (~$381M vs $378.7M a year ago) implies roughly flat. The FY25 acquisition pop is fully anniversaried.
• Room to run: the $1.4B cap is small, but the end-market (livestock health/nutrition) grows at GDP-ish rates; there is no TAM inflection here. Upside comes from multiple re-rating and debt paydown, not from compounding.
• Estimate quality caveat: FY29E–FY30E EPS rests on one analyst; treat the out-year "12% EPS CAGR" as a sketch, not a forecast.

Exponential Potential: Low (2/10). This can still be a perfectly good value/deleveraging trade — it is not, and will not be scored as, an exponential.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 (ended 2025-06-30) $1.296B, +27.4% (FY24 $1.018B, +4.1% on FY23 $977.9M). TTM through Q3 FY26: ~$1.500B. The step-change is the debt-funded acquisition landing in FY25, not organic acceleration.
• Quarterly trajectory (deceleration in plain sight): Q1 FY26 $363.9M (+39.7% YoY) → Q2 $373.9M (+20.9%) → Q3 $383.5M (+10.3%); Q4 FY26 Street estimate ~$381.2M vs $378.7M a year ago (~+0.7%).
• Margins: gross 32.5% TTM (FY25 30.9%, FY24 30.8%) — improving mix; EBITDA margin 15.0% TTM; operating margin 12.3% TTM; net margin 6.3%. Q3 FY26 operating income $48.0M on $383.5M revenue.
• Earnings & the GAAP/adjusted gap: TTM GAAP net income $95.2M / EPS $2.34; FY25 GAAP EPS was $1.19 vs the ~$2.03 adjusted consensus for that year — acquisition/integration costs, amortization and interest drive a persistent wedge. On the adjusted line the company has beaten four straight quarters: $0.57 vs $0.52 · $0.73 vs $0.59 · $0.87 vs $0.69 · $0.76 vs $0.72. Income quality TTM 0.69 (cash income lags accounting income — the working-capital build).
• Cash flow — the sore spot: FY25 operating CF $80.1M, capex $38.3M, FCF $41.8M. But on a TTM basis FCF has collapsed to ~$13M (FCF yield 0.92%; capex is 81% of OCF; cash-conversion cycle 202 days, inventory days ~195 with inventory at $444M, up from $266M FY24). FY23 FCF was negative $38.5M — this business regularly eats its own cash in inventory and plant.
• Balance sheet: total debt $761.6M, cash + ST investments $77.0M, net debt $693.5M → net-debt/EBITDA 3.25× TTM; debt/equity 2.18×; interest coverage 4.0×; quarterly interest expense has climbed to ~$10.9–13.1M (FY25 full-year interest expense $33.2M). Current ratio 3.17× and quick ratio 1.26× give near-term liquidity comfort; the leverage is a medium-term constraint, not an imminent one.
• Dividend: $0.48/share (~1.4% yield), ~$19.4M/year — only ~20% of GAAP net income, but more than the entire ~$13M TTM FCF; dividends-plus-capex coverage ratio is 0.91 (<1). Sustainable only if cash conversion normalizes.

6. Valuation — priced in or room?

On headline multiples PAHC screens cheap: 14.6× trailing GAAP EPS, ~11.1× FY26E / 10.2× FY27E adjusted EPS, 9.4× EV/EBITDA, 1.4× EV/sales, 0.9× price/sales. Forward PEG 1.43. The uncomfortable counter-metrics: P/FCF 108× and EV/FCF 166× on collapsed trailing free cash flow, P/B 3.83× on a thin $286M equity base under $1.08B of liabilities, and FMP's letter rating of B (overall 3/5; debt/equity and P/B both score 1/5). The honest frame: the earnings are cheap, the cash flow is not there yet, and the balance sheet mortgages the gap. If working capital normalizes and EBITDA holds ~$180M (FY29E consensus), the equity re-rates easily; if growth stalls at ~3% with leverage stuck above 3×, an 11× multiple is not obviously wrong. Street context: target $49 (high = low = median — one converged number, thin coverage) and a genuinely split grade sheet: 6 Buy, 4 Hold, 4 Sell. That 4-Sell tail is unusual for a "Buy-consensus" name and mirrors our Watch.

7. Technicals (from the tech block)

• Trend: broken. $34.13 sits below both the 50-DMA ($37.40) and the 200-DMA ($43.05), with the 50 below the 200 (death-cross posture). MACD −0.96 (negative).
• Location: −42.7% off the 52-week high ($59.58) — that is also the max drawdown from peak — and +30.7% off the 52-week low ($26.11). The insider-sale prices in the file timestamp the break: Chairman sales printed at $55.7–58.1 on May 5–6 and $47.6–48.3 on May 7 — a ~17% gap the day after the (beating) Q3 print, i.e. the market sold the outlook, not the quarter. The file does not contain the guidance detail; we flag the gap honestly rather than invent the cause.
• Momentum: RSI(14) 64 — a warm bounce off the $26 low, approaching but not at overbought; +2.6% on the day.
• Relative strength (the tell): −38.5% 3-mo vs SPY +14.6% / QQQ +23.6%; −8.6% 6-mo vs SPY +10.2%; still +22.2% 12-mo vs SPY +21.1%. Three months of severe underperformance inside a 12-month round trip.
• Read: this is a falling-knife recovery attempt, not a base. For a Watch name, the constructive sequence is: hold above ~$30, reclaim the 50-DMA (~$37), then let the 2026-08-26 guide confirm. Chasing the bounce front-runs the only catalyst that matters.

8. Moat & competitive position

Phibro's edge is regulatory registrations + entrenched distribution in food-animal health: approved animal-drug and feed-additive portfolios are slow and costly to replicate, relationships with integrated poultry/swine/cattle producers are sticky, and the added medicated feed additive portfolio deepens the core franchise. Mineral Nutrition and Performance Products are lower-margin, more commodity-like ballast. Limits of the moat: the giants of animal health are far larger and better-capitalized (the true comps — Zoetis, Elanco, Merck Animal Health — are absent from the FMP-supplied peer list), generic/price competition is persistent in antimicrobials, and antibiotic-use regulation is a structural headwind for parts of the legacy book. ROIC of 11.4% says the franchise earns above its cost of capital — a real but modest moat.

Peer set (FMP-supplied, market cap): ALVO $1.2B, ANIP $1.9B, AUPH $2.0B, AVDL $2.1B, BGM $76M, EVO $1.0B, MD $2.2B, MNKD $1.3B, OGN $3.6B, TLRY $0.5B. Data caveat: this is a generic specialty-pharma smallcap basket, not an animal-health cohort — none of these is a business comparable; judge PAHC against the animal-health majors instead.

9. Management, capital allocation & guidance

• Control & leadership: a family-controlled company. The profile lists Jack C. Bendheim as CEO; the most recent Form 4 (2026-07-01) tags Daniel M. Bendheim as "President and CEO" with a 300,000 performance-stock-unit award — an apparent leadership transition within the founding family. The data file does not document the handover; we flag the discrepancy rather than resolve it.
• Capital allocation: FY25 was the pivot year — $286.5M of acquisitions funded by $236.0M of net new debt, alongside the steady ~$19.4M dividend (paid every year on file) and zero buybacks in any year shown. Capex ~$38M/yr. This is an acquire-and-integrate playbook running on a leveraged balance sheet; deleveraging capacity is now the scoreboard.
• Insider activity (the most useful tell in the file): Chairman Jack Bendheim sold ~16,600 shares (indirect) across May 5–7 at $47.59–$58.13 — right around the top and through the post-earnings gap. Then director E. Thomas Corcoran bought 10,000 shares in the open market at $31.77 on 2026-05-29 — a genuine post-crash purchase, the single most bullish datapoint in this note. The July PSU award to Daniel Bendheim is routine compensation.
• Guidance: the data file contains no guidance text or earnings-call detail (no transcript on our plan). The four consecutive adjusted-EPS beats are documented; whatever was said on 2026-05-06 that halved the stock is not — an honest gap, resolved at the next print.

10. Catalysts & what to watch

• Next earnings: 2026-08-26 (Q4 FY26; Street adjusted EPS $0.72, revenue ~$381M). The quarter itself is nearly irrelevant — the initial FY27 guide is the entire event, given consensus already assumes only +3.3% FY27 revenue growth.
• Leverage trajectory: net-debt/EBITDA from 3.25× — any path below ~2.5× re-rates the equity; any drift toward 4× impairs it.
• Cash conversion: inventory ($444M) and the 202-day cash cycle unwinding into actual FCF — the single number that reconciles the cheap P/E with the 108× P/FCF.
• Vaccine line growth: the one clean product datapoint on file ($137.2M FY25, +13.5%) — the higher-value mix shift.
• Livestock-cycle & regulatory headlines: protein-producer economics, antibiotic-use rules in feed.

Thesis tripwires (what would change the call): a soft FY27 guide (revenue below ~flat or margin compression) → drops toward Avoid; net leverage above ~4× or a dividend cut → Avoid; conversely a clean FY27 guide with FCF inflecting positive, or a washout to ~$28 with leverage stable → upgrade to Buy — Tactical consideration.

11. Key risks

• Balance-sheet leverage (the dominant risk): $694M net debt at 3.25× EBITDA, 4.0× interest coverage, and rising interest expense (~$11–13M/quarter) — against ~$13M of trailing FCF. Little room for an operating stumble.
• Growth stall: the acquisition pop is anniversaried (quarterly YoY already faded to +10.3%); consensus sees ~3%/yr thereafter. A leveraged 3%-grower is fragile to any multiple compression.
• Cash conversion / working capital: 202-day cash cycle, $444M inventory, FCF negative as recently as FY23; the dividend currently exceeds TTM FCF.
• The unexplained May gap: the stock lost ~17% the day after a beating quarter and kept falling — the data file does not contain the reason. Underwriting a name where the market knows something the file doesn't is itself a risk; the Aug-26 print resolves it.
• Governance / family control: dual-role Bendheim family leadership, an apparent CEO transition not yet documented in our data, and Chairman sales near the top.
• End-market & regulatory: livestock-cycle swings, disease outbreaks cutting herd/flock counts, antibiotic-in-feed regulation, FX in the 43% non-US book.
• Estimate thinness: 1–4 analysts per line; FY29E–FY30E EPS is a single analyst. The "12% EPS CAGR" out-year story is weakly underwritten.
• No expert coverage: zero KB voices means no independent thesis — and no early warning from the panel if it breaks.

12. Verdict, position sizing & monitoring

Watch. Phibro is a real, defensive business (protein demand doesn't care about the cycle) trading at ~11× forward adjusted earnings after a 43% drawdown, with four straight beats, improving gross margin, an 11.4% ROIC and a director buying stock at $31.77. That is a genuinely interesting setup. But the honest ledger stops us from a Buy today: 3.25× net leverage with ~$13M of trailing FCF, growth decelerating to ~3% as the acquisition anniversaries, a broken tape below both moving averages, an unexplained guidance-driven crash, thin and split analyst coverage (4 Sells), and zero expert-panel conviction behind the name. Cheap plus leveraged plus stalling is exactly the combination that keeps getting cheaper — until a trigger says otherwise.

• Sizing: none today. If a trigger hits (a clean FY27 guide on 2026-08-26 with FCF inflecting, or a washout toward ~$28 ≈ 11× FY26E with leverage stable), enter as satellite, ≤1% of the flagship — small-cap, leveraged, family-controlled names get the smallest sleeve regardless of upside.
• Monitoring: re-underwrite at the 2026-08-26 print (guide, leverage, inventory); re-score each quarter. This verdict is logged as a tracked Synthos call as of 2026-07-06 at $34.13.
• Single biggest risk: the leverage — a 3.25× balance sheet meeting a growth stall means an operational wobble transmits straight to the equity.

Provenance & disclosures

• Traceability: 0 KB claims, 0 voices — a search of the Synthos knowledge base returns no PAHC coverage from any tracked expert. This note is fundamentals-driven by construction; kb_net_conviction is null because there is nothing to aggregate, and no conviction is fabricated.
• Data as-of: fundamentals 2026-03-31 (Q3 FY26 10-Q) · estimates & prices 2026-07-06 (FMP pull) · no KB claims. Forward figures are analyst consensus (FMP), labeled as estimates; out-year (FY29–FY30) EPS rests on a single analyst.
• Adjusted-vs-GAAP caveat: the Street's EPS line (~$3.07 FY26E) is adjusted; TTM GAAP EPS is $2.34 (income quality 0.69). Both are shown; the forward multiples quoted use the adjusted consensus.
• Acquisition-identity caveat: the FY25 cash-flow statement shows $286.5M of acquisitions; the attribution to the Zoetis medicated-feed-additive portfolio is widely-reported context, not a datapoint in the file.
• Segment caveat: FMP's product-segment data for PAHC is incomplete in recent years (FY25 shows only the Vaccines line); the last full three-segment split on file is FY22.
• Peer caveat: the FMP-supplied peer list is a generic specialty-pharma basket and omits the real animal-health comps (Zoetis, Elanco); judge against that cohort.
• Street-target caveat: the $49 "consensus" is a single converged value (high = low = median) — thin coverage, treated as context only.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").